(NATR) Natures Sunshine Products - Overview
Stock: Supplements, Herbals, Skincare, Oils
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 44.1% |
| Relative Tail Risk | -19.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.33 |
| Alpha | 71.46 |
| Character TTM | |
|---|---|
| Beta | 0.214 |
| Beta Downside | 0.221 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.66% |
| CAGR/Max DD | 0.92 |
Description: NATR Natures Sunshine Products January 01, 2026
Nature’s Sunshine Products, Inc. (NASDAQ:NATR) is a U.S.–based natural health and wellness company that develops, manufactures, and distributes a broad portfolio of nutritional supplements and personal-care items across North America, Europe, Asia, and Latin America. Its product lines cover blood-sugar support, bone and joint health, cognitive function, mood, sexual health, sleep, sports performance, vision, immune, cardiovascular, digestive health, as well as aloe-based skin and hair care, and weight-management solutions, sold under the Nature’s Sunshine and Synergy WorldWide brands through direct-to-consumer channels and an independent-consultant sales force.
Key recent metrics: FY 2023 revenue was approximately $200 million, with a 7 % year-over-year increase driven largely by e-commerce growth and expansion of the consultant network; cash and cash equivalents stood at $45 million, providing a liquidity runway of roughly 12 months at current burn rates. The global dietary-supplement market is projected to expand at a 7-8 % CAGR through 2028, fueled by an aging population and heightened consumer focus on preventive health-both macro trends that underpin NATR’s growth outlook. However, the company’s profitability remains pressured by high marketing spend and volatile raw-material costs, which means margin expansion will hinge on supply-chain efficiencies and scaling of higher-margin digital sales.
For a deeper, data-driven assessment of NATR’s valuation and risk profile, you may find ValueRay’s analytical toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 15.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 6.64 > 1.0 |
| NWC/Revenue: 21.59% < 20% (prev 21.65%; Δ -0.07% < -1%) |
| CFO/TA 0.14 > 3% & CFO 37.6m > Net Income 15.1m |
| Net Debt (-81.3m) to EBITDA (42.0m): -1.94 < 3 |
| Current Ratio: 2.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.0m) vs 12m ago -4.53% < -2% |
| Gross Margin: 72.28% > 18% (prev 0.71%; Δ 7157 % > 0.5%) |
| Asset Turnover: 186.0% > 50% (prev 181.4%; Δ 4.62% > 0%) |
| Interest Coverage Ratio: 385.9 > 6 (EBITDA TTM 42.0m / Interest Expense TTM 71.0k) |
Altman Z'' 5.87
| A: 0.39 (Total Current Assets 186.1m - Total Current Liabilities 83.6m) / Total Assets 264.8m |
| B: 0.27 (Retained Earnings 72.8m / Total Assets 264.8m) |
| C: 0.11 (EBIT TTM 27.4m / Avg Total Assets 255.1m) |
| D: 1.64 (Book Value of Equity 160.5m / Total Liabilities 98.1m) |
| Altman-Z'' Score: 5.87 = AAA |
Beneish M -2.80
| DSRI: 1.24 (Receivables 15.1m/11.4m, Revenue 474.5m/445.1m) |
| GMI: 0.99 (GM 72.28% / 71.43%) |
| AQI: 1.13 (AQ_t 0.12 / AQ_t-1 0.11) |
| SGI: 1.07 (Revenue 474.5m / 445.1m) |
| TATA: -0.09 (NI 15.1m - CFO 37.6m) / TA 264.8m) |
| Beneish M-Score: -2.80 (Cap -4..+1) = A |
What is the price of NATR shares?
Over the past week, the price has changed by +4.40%, over one month by +23.85%, over three months by +91.77% and over the past year by +79.73%.
Is NATR a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NATR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.5 | -14.5% |
| Analysts Target Price | 22.5 | -14.5% |
| ValueRay Target Price | 29.2 | 11% |
NATR Fundamental Data Overview February 03, 2026
P/E Forward = 24.2718
P/S = 0.9373
P/B = 2.7513
Revenue TTM = 474.5m USD
EBIT TTM = 27.4m USD
EBITDA TTM = 42.0m USD
Long Term Debt = 14.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.60m USD (from shortTermDebt, last quarter)
Debt = 14.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -81.3m USD (from netDebt column, last quarter)
Enterprise Value = 363.5m USD (444.8m + Debt 14.3m - CCE 95.6m)
Interest Coverage Ratio = 385.9 (Ebit TTM 27.4m / Interest Expense TTM 71.0k)
EV/FCF = 11.63x (Enterprise Value 363.5m / FCF TTM 31.3m)
FCF Yield = 8.60% (FCF TTM 31.3m / Enterprise Value 363.5m)
FCF Margin = 6.59% (FCF TTM 31.3m / Revenue TTM 474.5m)
Net Margin = 3.18% (Net Income TTM 15.1m / Revenue TTM 474.5m)
Gross Margin = 72.28% ((Revenue TTM 474.5m - Cost of Revenue TTM 131.5m) / Revenue TTM)
Gross Margin QoQ = 73.28% (prev 71.72%)
Tobins Q-Ratio = 1.37 (Enterprise Value 363.5m / Total Assets 264.8m)
Interest Expense / Debt = 0.18% (Interest Expense 26.0k / Debt 14.3m)
Taxrate = 42.77% (4.14m / 9.67m)
NOPAT = 15.7m (EBIT 27.4m * (1 - 42.77%))
Current Ratio = 2.22 (Total Current Assets 186.1m / Total Current Liabilities 83.6m)
Debt / Equity = 0.09 (Debt 14.3m / totalStockholderEquity, last quarter 160.5m)
Debt / EBITDA = -1.94 (Net Debt -81.3m / EBITDA 42.0m)
Debt / FCF = -2.60 (Net Debt -81.3m / FCF TTM 31.3m)
Total Stockholder Equity = 158.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.92% (Net Income 15.1m / Total Assets 264.8m)
RoE = 9.51% (Net Income TTM 15.1m / Total Stockholder Equity 158.7m)
RoCE = 15.84% (EBIT 27.4m / Capital Employed (Equity 158.7m + L.T.Debt 14.3m))
RoIC = 9.88% (NOPAT 15.7m / Invested Capital 158.7m)
WACC = 6.49% (E(444.8m)/V(459.1m) * Re(6.70%) + D(14.3m)/V(459.1m) * Rd(0.18%) * (1-Tc(0.43)))
Discount Rate = 6.70% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.57%
[DCF Debug] Terminal Value 81.30% ; FCFF base≈23.8m ; Y1≈19.5m ; Y5≈13.8m
Fair Price DCF = 24.99 (EV 355.9m - Net Debt -81.3m = Equity 437.2m / Shares 17.5m; r=6.49% [WACC]; 5y FCF grow -21.80% → 2.90% )
EPS Correlation: 38.60 | EPS CAGR: 15.46% | SUE: -1.17 | # QB: 0
Revenue Correlation: 56.21 | Revenue CAGR: 2.28% | SUE: 2.04 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.18 | Chg30d=-0.035 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=1.00 | Chg30d=+0.125 | Revisions Net=+1 | Growth EPS=-13.4% | Growth Revenue=+3.5%